Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Retinoblastoma 2Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous-Cell Lung Cancer 1Sjogren's Syndrome 1Scleroderma, Systemic 1Retinal Neoplasms 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Resectable Non-small Cell Lung Cancer 1Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Psoriasis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Cancer Recurrent 1Oropharyngeal Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1NSCLC 1Multiple Sclerosis 1Melanoma 1Lymphatic Metastasis 1

Interventions

Cisplatin 160Fluorouracil 134Paclitaxel 125Radiotherapy 117Oxaliplatin 87Docetaxel 70Carboplatin 70Irinotecan 59pembrolizumab 57Capecitabine 57Leucovorin 56Radiation 47Surgical Procedures, Operative 33Drug Therapy 33Esophagectomy 31Cetuximab 25Neoadjuvant Therapy 24Nivolumab 23Bevacizumab 21Trastuzumab 20camrelizumab 19S 1 (combination) 19Chemoradiotherapy 17Albumin-Bound Paclitaxel 16Magnetic Resonance Spectroscopy 15Epirubicin 15tislelizumab 14Taxes 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Esophageal Neoplasms × Platinum Compounds × Clear all
NCT04821778 2026-01-21

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3 Recruiting
2,000 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT04821843 2026-01-21

Neoadjuvant Treatment Modalities in Esophageal Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3 Recruiting
2,000 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Henan Cancer Hospital

Phase 2 Unknown
132 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡